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1. Introduction 
Cardiovascular disease still remains the leading cause of deaths worldwide in both males 
and females. A variety of factors have been associated to play a role in the development of 
this disease, such as an individual’s genetic background and continual life style factors. 
Life style factors (including diet) have greatly influenced the occurrence and progression 
of this disease. The medical profession has made great efforts to adequately address and 
to continually stress to their patients an altered life style to confront the non-genetic 
factors, in order to potentially minimize their risk for cardiovascular disease. This 
campaign has centered on a continual direction for refinements in diet, regular exercise, 
smoking cessation, and to control blood pressure to lower their risk for cardiovascular 
disease.  
The World Health Organization has reported that approximately 17 million people die of 
cardiovascular diseases, including myocardial infarcts and strokes, every year. [1] The most 
common type of cardiovascular disease is atherosclerosis, which has shown to progress 
overtime. This progression involves the narrowing of our arteries, which ultimately limits 
the delivery of oxygen to viable tissue beds. [2] Atherosclerosis is not confined to a sole 
anatomic region; for it can eventually progress to involve many arterial vessels in our 
circulation, producing not only heart disease, but cerebrovascular and peripheral vascular 
devastating pathological sequelae. Financially, cardiovascular diseases have taxed 
economies and current trends have shown its continued burden on healthcare dollars 
worldwide.  
The progression of coronary arterial atherosclerosis has the potential to eventually 
produce myocardial ischemia, reflected in clinical symptoms of angina or chest pain. This 
atherosclerotic state produces a decrease in blood flow to the myocardium, producing a 
decrease availability of oxygenated blood to these muscular regions of the heart. 
Clinically, patients afflicted with coronary artery disease/myocardial ischemia can 
experience symptoms of angina or chest pain, commonly during and following stressful 
situations; however, some unfortunately can even have episodes at rest. Furthermore, 
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with the progression of coronary artery disease and the development of significant 
coronary arterial atherosclerosis, patients are susceptible of sustaining an acute 
myocardial infarction or live with a chronic, debilitating condition, which has the 
potential of advancing into the development of heart failure.  
Along with significant myocardial ischemic coronary arterial disease, many patients can 
experience functional abnormalities, such as diastolic dysfunction or an abnormality in 
ventricular relaxation. This ventricular dysfunctional condition has continued to be a 
challenging clinical problem for physicians because as of today, there is not yet an 
approved effective, solely directed therapy for myocardial diastolic dysfunction. Current 
medical investigations have found that left ventricular diastolic dysfunction is more 
prevalent than expected. Redfield et al. reported in 2042 randomly selected adults over 
the age of 45 that 21% had mild and 7% had at least moderate diastolic dysfunction. Six 
percent had moderate or severe diastolic dysfunction with a normal ejection fraction. [3] 
This has been supported by additional published studies that have shown that diastolic 
dysfunction exists with its prevalence varying with age. Fischer et al. found diastolic 
dysfunction in 2.8% of individuals between 25-35 years of age and increasing to 15.8% 
among those older than 65 years of age. Compared to women, men had a higher rate of 
diastolic abnormalities (13.8% vs. 8.6%). Factors associated with diastolic abnormalities 
have included arterial hypertension, evidence of left ventricular hypertrophy and 
coronary artery disease. Additionally, diastolic dysfunction has been related to a higher 
body mass index, high body fat and diabetes mellitus. [4] Unfortunately, when diastolic 
dysfunction develops early in the post myocardial infarction clinical period, these patients 
tend to have a poorer outcome.  
Myocardial ischemia is a common entity in the development of congestive heart failure 
(CHF) and many of these patients will have a component of diastolic dysfunction. Clinically, 
at least half of patients diagnosed with CHF will have a degree of diastolic dysfunction 
solely or in combination with systolic dysfunction. These CHF patients with diastolic 
dysfunction can have a challenging therapeutic course and a less favorable clinical outlook. 
Ingwall and Weiss proposed that the failing heart is energy starved. However, this theory is 
not novel. This theory was previously proposed, but was not actively pursued because it 
was unclear whether ATP levels really decreased and if these levels did decrease in the 
failing heart, then the remaining pool of ATP compounds should be sufficient to satisfy 
myocardial ATP-requiring reactions. [5] Currently, there appears to be renewed interest in 
this hypothesis; that the failing heart is energy starved. The advancement in biophysical 
tools, such as nuclear magnetic resonance (NMR) spectroscopy and positron emission 
tomography (PET) scans have aided in providing a better understanding of this myocardial 
energy/functional relationship.  
2. Cellular energy and function during and following myocardial ischemia: A 
potential role for D-ribose 
2.1 Pre-clinical investigations 
All cells require high energy phosphates, predominantly ATP, to maintain their integrity 
and function. Normally, the cellular supply of ATP meets tissue demands. Glycolysis and 
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the tricarboxylic acid cycle pathways produce ATP compounds with glucose as the starting 
substrate. However, cells can also rely on alternative pathways, such as the hexose 
monophosphate shunt or pentose phosphate pathway for the production of energy 
molecules. [6] As stated, the supply of ATP is essential to preserve cellular cardiac energy 
and function; and without these levels of ATP, a myocyte’s integrity and function is 
jeopardized. When myocytes are subjected to ischemia, there is a depletion in energy stores, 
which can potentially decrease intracellular reactions, including cellular function. 
Obviously, if this ischemic insult is severe enough, viability can be affected. Besides this 
assumed immediate depletion in ATP levels, numerous studies have shown that this 
depletion in myocardial ATP levels from ischemia lasts for a considerable time period due 
to slow adenine nucleotide synthesis, of which this delay in ATP recovery is reflected in 
abnormal function. [7] Because of these published findings, future developed methods 
directed at enhancing the recovery of this energy deficiency due to ischemia should strongly 
be considered in the therapeutic management of myocardial ischemic diseases.  
There is a direct interaction between adequate myocardial ATP levels and the development 
of ventricular dysfunction, predominantly diastolic dysfunction. Calcium plays a major role 
in this interaction, which is an energy dependent process. Adenosine triphosphate provides 
the energy for this interaction between cytosolic calcium and the sarcoplasmic reticulum. 
Depleted ATP levels can result in calcium remaining fixed to troponin longer in diastole, 
producing a state of diastolic dysfunction or altered ventricular compliance. Following 
ischemia, a return in diastolic function may be limited by the availability of the high energy 
phosphate, ATP. [8] Theoretically, efforts to maximize the recovery of myocardial ATP 
levels during and following ischemia could aid in minimizing the functional untoward 
effects following ischemia. 
Research over decades has explored the relationship of myocardial ATP levels during and 
following ischemia. Most of these initial myocardial ischemic studies involved acute 
isolated heart models, mainly Langendorff or Neely preparations. Reibel and Rovetto 
reported in isolated perfused rat hearts that a moderate ischemic insult (10-30 minutes) 
resulted in a 50-70% decrease in myocardial ATP levels. [9] The recovery of myocardial 
ATP levels following ischemia is not prompt with reperfusion. Hours to days are required 
for substantial recovery, depending upon the degree of the ischemic insult. Kloner et al. 
found that the recovery of ATP compounds after 15 minutes of coronary occlusion in the 
healthy canine heart was only 75% restored after three days with one week required for 
full recovery. [10] Likewise, Zimmer concurred that an extended time period is required 
for the recovery of depressed myocardial energy levels, as well as a measured 
improvement in the alteration in mechanical function following ischemia. [11] Even 
though these isolated myocardial experimental models have provided important findings, 
they have limitations due to the nature of the isolated heart preparation. Therefore, 
experiments involving an intact animal model would be essential to support these initial 
isolated heart preparation findings. Short term investigations involving an intact animal 
model found similar findings in measured myocardial adenine nucleotide levels following 
ischemia. Twelve to 30 minutes of myocardial ischemia produced a substantial drop in 
ATP levels with a significant decrease in total adenine nucleotides, and days were 
required for total recovery. [12]  
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However, to fully appreciate this important energy-functional relationship, a chronic 
animal model to measure both myocardial energy levels and function would be ideal to 
better understand the long term effects of ischemia. A chronic canine animal model was 
developed to provide the means for long term assessment of myocardial energy levels and 
function during and following ischemia. [13-15] Using this chronic model, 20 minutes of 
normothermic myocardial ischemia produced a significant decrease (approximately 50%) 
in ATP levels, which was accompanied with a state of left ventricular diastolic 
dysfunction. Furthermore, the data from this chronic animal study confirmed that the 
effects of myocardial ischemia have a long term effect. Researchers reported that there was 
a substantial delay, over one week, in myocardial energy levels and functional recovery 
following a moderate, reversible ischemic insult. [13-15] 
Ward et al. reported that myocardial precursor availability is an important limiting factor in 
the recovery of myocardial ATP molecules following an ischemic insult. [15] Many 
researchers have investigated various substrates and methods in replenishing depressed 
levels of ATP following ischemia. Investigations with adenine nucleotide precursor 
substrates have included adenosine, 5-amino-4-imidazolecarboxamide riboside, inosine, 
adenine, D-ribose, as well as an adenine degradative enzymatic inhibitor (erythro-9-(2-
hydroxy-3-nonyladenine hydrochloride). However, these studies have reported mixed 
results in the recovery of energy molecules and function following ischemia. The majority of 
these precursors have at best shown a minimal improvement in both ATP recovery and 
function. However, this was not the case when investigating the effects of D-ribose during 
and following myocardial ischemia. D-ribose, a natural occurring pentose carbohydrate, 
supplementation demonstrated in numerous animal studies its significant benefit in 
enhancing the return in ATP levels and improved function following global and regional 
myocardial ischemia. Zimmer and Gerlach reported that supplementation with D-ribose in 
adult, isolated rat hearts resulted in an increase rate of adenine nucleotide synthesis. [16] 
Pasque et al. found similar results in isolated, perfused, working rat hearts subjected to 15 
minutes of ischemia, followed by 2-15 minutes of myocardial work. D-ribose 
supplementation improved the recovery in myocardial ATP levels along with a mean 
percent improvement in functional recovery. [17] St. Cyr et al. also observed the benefits of 
D-ribose and adenine in a chronic animal model. Supplementation with D-ribose and 
adenine following 20 minutes of global ischemia resulted in 85% return in ATP levels as 
compared to no ATP recovery without D-ribose and adenine. [18]  
In the same chronic canine model design described by St.Cyr et al. with additional 
functional instrumentation, Schneider et al. reported similar ATP benefits with D-ribose 
and adenine, as well as improvements in left ventricular non-compliance/diastolic 
dysfunction following 20 minutes of global myocardial ischemia. [13,19] Further 
investigations revealed the sole benefits of D-ribose during and following ischemia. 
Tveter et al. investigated the benefits of D-ribose alone in a chronic canine model, in 
which hearts were subjected to a moderate (20 minutes) global myocardial ischemic 
insult. They found that D-ribose solely produced similar benefits in both myocardial 
energy levels and functional recovery following global ischemia, as was previously 
reported with D-ribose and adenine. [20] D-ribose appeared to solely enhance the 
recovery of myocardial adenine nucleotide levels, improve diastolic dysfunction and the 
adenine nucleotide pool following ischemia. 
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A significant restrictive or narrowing of a coronary arter(ies) can potentially result in an 
acute occlusion or an acute myocardial infarct, for which myocardial dysfunction post 
infarct can be present. Following infarction, some of these hearts can experience a continual 
decline in function, leading to the development of heart failure. The remote myocardium not 
involved in the infarcted tissue is subjected to an increased workload, which can severely 
tax its myocardial energy supply, which over time can affect remodeling. Zimmer et al. 
reported in adult rats that a decline in left ventricular hemodynamics occurs following 
myocardial infarction. They observed a progressive decline in left ventricular systolic 
pressure, a decline in left ventricular dP/dtmax, elevated left ventricular end diastolic 
pressure, and lower cardiac outputs and stroke volume indices post infarction. Upon 
supplying the substrate D-ribose, there was an improvement in the above measured left 
ventricular hemodynamic parameters with stimulation in adenine nucleotide synthesis. [21] 
Likewise, Befera et al. observed similar findings with the supplementation of D-ribose 
following acute myocardial infarction in adult rats. They found an improvement in left 
ventricular function in the remote left ventricular areas when supplying D-ribose. There was 
increased contractility and myocardial wall thickness with less ventricular dilatation with D-
ribose supplementation. [22] 
These two pre-clinical, animal studies reported that D-ribose prevented or delayed the 
development of left ventricular dysfunction following acute myocardial infarction. Hence, 
the question posed is: might D-ribose offer an additional benefit, if supplemented prior to a 
myocardial infarction? When D-ribose was supplied pre-infarction, Gonzalez et al. reported 
that providing D-ribose in adult rats resulted in a significant reduction in the created left 
ventricular infarct area and a significant improvement in left ventricular function when 
assessed at 6 hours post infarct. Left ventricular systolic pressure and contractility were 
restored to normal levels with a significant improvement in measured parameters of left 
ventricular relaxation with supplemental D-ribose. [23]  
2.2 Clinical D-ribose evaluation 
The observed positive energy enhancing and functional benefits associated with D-ribose in 
the pre-clinical investigations initiated subsequent clinical studies to further assess its 
potential in patients afflicted with cardiovascular diseases. Because of the benefits of D-
ribose during and following ischemia, researchers investigated this potential in enhancing 
the identification of hibernating myocardium. Hibernating myocardium represents regional 
areas of myocardial dysfunction due to prolonged hypoperfusion or ischemia. This 
condition can be reversed upon restoration of a more adequate level of blood flow to these 
regions. Theoretically, efforts to aid in the identification of these regions can help in the 
management strategies for revascularization. Current methods in identifying these regions 
include Thallium-201 scans, dobutamine stress echocardiography, PET, and magnetic 
resonance imagery. Hibernating myocardium is likely to be associated with lower levels of 
myocardial ATP; and therefore, supplementation with an adenine nucleotide agent might 
aid in further identifying these viable regions. D-ribose has demonstrated a benefit in this 
identification process. Before undertaking clinical investigations, pre-clinical animal studies 
demonstrated the identification benefit of D-ribose in hibernating myocardium. In the 
clinical realm, Perlmutter et al. reported that D-ribose identified more reversible defects 
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using Thalium-201 scans. [24] Other clinical studies have supported this finding. Hegewald 
et al. found that D-ribose also increased the detection of viable ischemic myocardial regions 
using SPECT Thallium imaging. [25] More recently, Sawada et al. demonstrated that the 
supplementation of D-ribose provided anti-ischemic effects with improving the 
identification of wall motion dysfunctional abnormalities during dobutamine stress 
echocardiography. [26]  
Previously reported positive pre-clinical animal studies demonstrating the benefits of D-
ribose during and following ischemia generated additional clinical investigative interest. 
Since D-ribose has shown in animal studies to enhance the recovery in ATP levels and 
improve function following myocardial ischemia, Pliml et al. argued that there is significant 
impairment in ATP levels in the ischemic myocardium. The current lack of therap(ies) 
directed to the restoration or preventing further decrease in these myocardial energy 
compounds lead the researchers to design a study in which patients with stable coronary 
artery disease underwent serial treadmill exercise testing while supplementing with D-
ribose. D-ribose demonstrated significant benefits in increasing treadmill exercise time 
before the onset of angina and/or ischemic electrocardiographic changes. [27] 
Myocardial ischemia is an etiological factor in the development of CHF and reports have 
proposed that the failing heart is energy starved. [5] Because of D-ribose’s ability to 
enhance the recovery of myocardial ATP levels and improve diastolic dysfunction 
following ischemic, Omran et al. investigated the role of D-ribose in class II-III CHF 
patients. They reported both objective and subjective benefits with D-ribose. There was an 
improvement in diastolic dysfunctional parameters, as assessed by serial 
echocardiographic examinations; and subjectively, the patients experienced an improved 
quality of life and physical function. [28]  
Commonly, CHF patients complain of shortness of breath and fatigue. As their failure 
progresses, patients have a decrease in their ventilatory efficiency. Carter et al. found that 
supplementation with D-ribose enabled class II-III CHF study patients with left ventricular 
dysfunction to maintain their VO2max, improve their ventilatory efficiency and experience a 
positive trend in their daily quality of life assessment. [29] Vijay et al. concurred in a 
separate clinical study the positive benefits of D-ribose in class II-IV CHF patients. They 
observed significant improvements in ventilatory efficiency in class III-IV patients with a 
positive, but not statistically significant, .trend in improved ventilator efficiency in class II 
patients. [30] 
The use of D-ribose has also been explored in cardiovascular surgery. Alterations in 
myocardial function have been observed in the post-ischemic interval following surgery. 
Wyatt et al. found that the use of a cardioplegic solution containing adenosine, 
hypoxanthine and D-ribose during intra-operative ischemia maintained myocardial 
energy levels during ischemia and with reperfusion resulted in enhanced functional 
recovery post operatively. [31] Vance et al. reported that parenteral use of D-ribose in 
patients undergoing elective aortic valve replacement with or without accompanying 
coronary arterial bypass grafting resulted in the maintenance in ejection fraction 
postoperatively, unlike the decline in ejection fraction observed in the patients not 
receiving D-ribose. They concluded that the treatment regimen of D-ribose preserved left 
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ventricular function peri-operatively. [32] More recently, oral D-ribose was added to a 
metabolic designed protocol for patients undergoing off pump coronary artery bypass 
revascularization procedures. Perkowski et al. found that this D-ribose metabolic protocol 
resulted in lower mortality and morbidities, along with a significant early postoperative 
improvement in cardiac index in patients undergoing “off pump” coronary artery 
revascularization. [33]  
3. Summary 
Even with the advances in cardiovascular medical technologies over decades, 
cardiovascular disease still ranks as the leading cause of death worldwide for both males 
and females. Myocardial ischemia, a factor in cardiovascular disease, has continued to be a 
leading cause of deaths in middle to elderly aged individuals. With continued current 
aggressive education, there have been strides in addressing the cardiovascular risk factors in 
this disease, including refinements in diet, regular exercise, smoking cessation, and blood 
pressure control. However, the underlying metabolic energy deficiency found with 
myocardial ischemia still requires further attention.  
Every cell requires adequate levels of high energy phosphates, i.e. ATP, to maintain its 
integrity and function. Myocardial ischemia lowers myocardial ATP levels, which has 
shown to reflect functional abnormalities. Relaxation of the myocardium, occurring during 
diastole, requires adequate ATP levels for the normal flux of calcium interacting with the 
sarcoplasmic reticulum. Without adequate levels of myocardial ATP, a state of ventricular 
diastolic dysfunction or non-compliance develops. Over decades research has centered on 
developing strategies in replenishing deficient levels of ATP during and following 
myocardial ischemia. The abundance of research has entertained on providing metabolic 
substrates to regenerate ATP compounds following ischemia. The results of these numerous 
investigations have been mixed; however, supplementation with D-ribose, a natural 
occurring pentose carbohydrate, has been found to not only to enhance the recovery of ATP 
levels, but to aid in improving the state of ventricular diastolic dysfunction following 
myocardial ischemia. D-ribose has shown to improve ventricular compliance following 
ischemia, for which there is not an approved marketed device or pharmaceutical that can 
offer this functional benefit.  
The clinical therapeutic cardiovascular uses of D-ribose continue to expand. Published 
studies have reported its potential benefits, such as in acute and chronic myocardial 
ischemic conditions, identifying hibernating myocardium, in CHF patients, and its use in 
the peri-operative cardiovascular surgical patient. The literature has provided support 
that supplemental D-ribose may offer the means to enhance the recovery of myocardial 
cellular energy with functional benefits in patients afflicted with ischemic cardiovascular 
disease.  
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